Dynex Technologies

Dynex Technologies

Automates ELISA and chemiluminescence microplates

Overview

Dynex Technologies develops and manufactures fully automated ELISA and chemiluminescence microplate instruments and related accessories. These systems automate the processing of diagnostic tests in laboratories by handling continuous sample loading, performing automated results calculations, and offering an intuitive graphical user interface to minimize training and hands-on time. The products are designed for high-throughput operations and regulatory compliance, supported by software that streamlines workflows and quality controls. Dynex serves a global market with direct sales in the United States and distributor partnerships in over 120 countries, and has installed more than 8,500 instruments worldwide. The company aims to boost laboratory productivity, accuracy, and compliance in the diagnostics field through reliable automation and strong customer service.

About Dynex Technologies

Simplify's Rating
Why Dynex Technologies is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Hardware

Industrial & Manufacturing

Enterprise Software

Healthcare

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Chantilly, Virginia

Founded

1952

Get referred to Dynex Technologies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • DS2 Elite commercial launch expands upgrades across regulated clinical and biopharma labs.
  • ALPCO's AutoPlex GI panel widens Dynex into higher-value multiplex biomarker testing.
  • Dynex cites 8,500 installations worldwide, creating recurring consumables and service pull-through.

What critics are saying

  • The 2025 Agility tip recall shows quality-control failures that disrupt patient-result turnaround.
  • Dynex relies on consumables and installed base; one product defect can trigger repeat recall costs.
  • ALPCO and other partners can bypass Dynex if they choose competing automation platforms.

What makes Dynex Technologies unique

  • DS2 Elite launched January 2026 with Windows 11 and Co-Connect LIS integration.
  • ALPCO partnership automates multiplex GI biomarkers on Dynex chemiluminescence analyzers.
  • Dynex sells U.S.-manufactured, ISO-certified systems supporting 1,000 assay protocols.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

↑ 4%

1 year growth

↑ 4%

2 year growth

↑ 4%
GlobeNewswire
Nov 12th, 2024
Elisa Analyzers Market Size Forecast To Hit Usd 960.7 Million By 2031, Growing At A Cagr Of 5.9%| Says Transparency Market Research, Inc.

Wilmington, Delaware, United States, Transparency Market Research, Inc. , Nov. 12, 2024 (GLOBE NEWSWIRE) -- The ELISA analyzers market was valued at US$ 574.7 million in 2022. Between 2023 and 2031, it is expected to expand at a CAGR of 5.9% and surpass US$ 960.7 million during the forecast period. The development of technology could lead to ELISA analyzers that are more sophisticated and efficient. Faster analysis times, improved automation, and enhanced sensitivity could increase adoption.ELISA (Enzyme-Linked Immunosorbent Assay) is widely used in the medical field and in pharmaceutical research, among other fields

ALPCO
Dec 15th, 2022
5 Reasons to Add GI Biomarker Testing to Your Lab’s Menu

ALPCO has partnered with Dynex Technologies to offer the first automated multiplex GI protein biomarker test.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Dynex Technologies right now.

Find jobs on Simplify and start your career today

We update Dynex Technologies's jobs every few hours, so check again soon! Browse all jobs →